Company builds on deep structure-based drug design capabilities to add protein therapeutics to pipeline: BCX17725 for Netherton syndrome — entering clinic in 2H 2024Bifunctional fusion protein enabling simultaneous inhibition of multiple complement pathways to better address complex complement-mediated diseases — entering clinic in 2025 Oral C5 program for generalized myasthenia gravis — entering clinic in 2025Combination of avoralstat with SCS Microinjector® from Clearside enables direct delivery into the suprachoroidal space in the eye to treat patients with DME — entering clinic in 2025 RESEARCH TRIANGLE PARK, N.C., Nov.

该公司建立在基于深层结构的药物设计能力的基础上，将蛋白质疗法添加到管道中：BCX17725用于Netherton综合征-在2H 2024进入临床双功能融合蛋白能够同时抑制多种补体途径以更好地解决复杂的补体介导的疾病-于2025年进入临床广泛性重症肌无力的口服C5计划-2025年进入诊所avoralstat与Clearside的SCSMicroInjector®相结合，可直接进入眼内脉络膜上腔治疗DME患者-于2025年进入诊所RESEARCH TRIANGLE PARK，N.C.，Nov。

03, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced updates from its drug discovery process and additional therapies from its pipeline that the company will highlight at a Research and Development (R&D) Day today at 1:00p ET at the company’s Discovery Center of Excellence in Birmingham, Alabama.

032023（GLOBE NEWSWIRE）-BioCryst Pharmaceuticals，Inc。（纳斯达克股票代码：BCRX）今天宣布其药物发现过程的更新以及该公司将在今天的研发（R＆D）一天强调的其他治疗方法。在阿拉巴马州伯明翰的公司发现卓越中心1:00p ET。

A live webcast of the event will be available online in the investors section of the company website at www.biocryst.com. “The success we are achieving with ORLADEYO demonstrates that when we deliver a first-in-class or best-in-class medicine, we can change patients’ lives. The focus of our discovery efforts is to leverage our 30-plus years of experience to bring more first-in-class or best-in-class medicines to patients living with complement-mediated and other rare diseases.

该活动的实时网络广播将在公司网站的投资者部分www.biocryst.com在线提供。“我们用ORLADEYO取得的成功表明，当我们提供一流或一流的药物时，我们可以改变患者的生活。我们的发现工作的重点是利用我们30多年的经验为患有补体介导和其他罕见疾病的患者带来更多一流或一流的药物。

The team is excited to share our approach, and our expanded pipeline of new programs, at our R&D Day,” said Jon Stonehouse, president and chief executive officer of BioCryst. “We have significantly diversified our pipeline and we continue to be disciplined around decisions to invest further only when a program meets the high bar we have set of f.

BioCryst总裁兼首席执行官Jon Stonehouse说，团队很高兴分享我们的方法，并在我们的研发日扩大了新项目的渠道。“我们已经使我们的管道显着多样化，并且我们继续受到关于进一步投资的决定的纪律处分，只有当计划达到我们设定的f的高标准时。